Heart risk from sarcoma chemo: can we predict it before it happens?
NCT ID NCT06511388
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study aimed to find early markers of heart damage in people with sarcoma receiving a common chemotherapy drug (doxorubicin). Researchers used advanced heart ultrasound techniques to track changes over time. The goal was to identify which patients are at highest risk for heart failure before serious damage occurs. The study was terminated early, but it involved 400 participants at Mayo Clinic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.